Auris Medical (EARS) Earns Daily Media Sentiment Score of 0.08

Media coverage about Auris Medical (NASDAQ:EARS) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Auris Medical earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5019871387937 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s rankings:

Auris Medical (NASDAQ EARS) remained flat at $$0.29 during mid-day trading on Friday. 980,539 shares of the company traded hands, compared to its average volume of 1,108,342. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04. The firm has a market capitalization of $17.58, a price-to-earnings ratio of -0.44 and a beta of 0.11. Auris Medical has a 1 year low of $0.25 and a 1 year high of $1.06.

Auris Medical (NASDAQ:EARS) last posted its quarterly earnings results on Tuesday, November 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.

Separately, ValuEngine raised Auris Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

TRADEMARK VIOLATION NOTICE: “Auris Medical (EARS) Earns Daily Media Sentiment Score of 0.08” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit